Abstract
e11541 Background: Triple-negative breast cancer certainly becomes the interested subgroup of breast cancer because of poorer outcomes. In term of clinicopathologic features, response rate in chemotherapeutic agents and survival outcomes relatively differ from hormone positive and HER-2 positive groups. So we would like to identify the prevalence and epidemiologic data of this subgroup in Thai patients and compare to several datas. Methods: One hundred and fifty-three triple negative breast cancer patients diagnosed and treated at the King Chulalongkorn Memorial Hospital during 2003-2010 were retrospectively reviewed. The clinicopathologic features were collected from medical records. In addition, the outcomes of chemotherapy treatment and survival rate were analyzed. Results: Invasive ductal carcinoma was identified 86.9%. Average age was 47.9 years. (Range 26-79 years) Early and locally advanced stages were found 77.6% and 19.1%, respectively. The clinicopathologic features were high grade (70%), tumor size T2 54.7%, p53 positive 67%, Ki-67 positive 97% (Ki-67 more than 30% in 78.6%), lymphatic invasion 40.3%, LN negative 59.2%. 62.9% underwent modified radical mastectomys. Axillary node resections were performed 86.3%. In neoadjuvant treatment subgroup (45 patients), anthracycline-based regimens were prescribed in 88.9% and overall response rate was 77.8%, particularly pCR 24.4%. After average 34 months follow-up (Range 3-120 months), twenty-nine death patients were observed. Most common sites of recurrence were visceral, lung and brain metastases. Conclusions: The prevalence and clinicopathologic features of triple-negative breast cancer in Thai patients were similar to the results previously published by other researchers. Chemotherapy treatment outcomes in this subgroup had significantly identified better than hormone positive group.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call